Skip to main content
NUTX logo

NUTX · Nutex Health Inc.

Track NUTX — free
$187.42 +0.61 (+0.33%) At close · Aug 14
Market Cap
$1.28B
Shares
6.85M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$187.42 Open$186.81 Day$182.32–195.00 52W close$80.92–197.51 Avg vol 30d145K Short int1.1M · 16.1% float · 9.0d Short vol68% Last earningsAug 7, 2026 DataJul 2024–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Jul 3, 2024; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +38%
      above
      Price vs 50-day avg +17%
      above
      RSI (14) 60
      neutral
      MACD trend Positive
      52-week position 91%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +15%
      trailing
      6-month return +84%
      trailing
      YTD return +14%
      this year
      Relative strength +70%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $161 › 200d $136 — 50d above 200d
      Institutional flow Accumulating
      +16% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      16.13% of float · ▲ +5.2% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      150 holders — near 3-yr high, broad support
      Squeeze score 96
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +82%
      Y/Y
      Gross margin 51%
      expanding
      EPS growth +8%
      Y/Y
      Free cash flow $245.6M
      Buyback $19.8M
      remaining
      Balance sheet $67.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 95%
      annualized · 1-yr
      Max drawdown −54%
      past year
      ATR 7.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 6, 2026
      Normalized historical contract services expenses · prospectively 25% – 30%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +38% Bullish
      Price vs 50-day avg
      +17% Bullish
      RSI (14)
      60 Neutral
      MACD trend
      Positive Bullish
      52-week position
      91% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $161 › 200d $136 — 50d above 200d
      Institutional flow Accumulating
      +16% holders QoQ · +38 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      16.13% of float · ▲ +5.2% MoM · 9.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      150 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $81 Now $187 · 91% Range high $198
      vs 200-day avg +38% vs 50-day avg +17%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP $147.55M Six Months Ended June 30, 2026
      EBITDA non-GAAP $162.45M Six Months Ended June 30, 2026
      Hospital facilities 27 Three Months Ended June 30, 2026

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NUTX
      Nutex Health Inc.
      this stock
      $1.28B +13.9% +82.4% 16.1%
      HCA
      HCA Healthcare, Inc.
      $89.77B -13.3% +7.1% 13.9 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      $30.87B -4.4% 0.0%
      THC
      Tenet Healthcare Corp
      $21.57B +34.8% +0.9% 10.3 4.0%
      FMS
      Fresenius Medical Care AG
      $12.65B -0.2% +5.9% 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      150
      % held
      42.0%
      Net QoQ
      +76.7K sh
      Top holder
      Pertento Partners LLP
      Held Float
      View
      Held by Funds
      Fund positions
      154
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      1.1M
      Days to cover
      9.0d
      Change
      +54.4K sh
      View
      Short Volume
      Short vol %
      68%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2
      Value
      $358
      As of
      Jul 14, 2026
      View
      Off-Exchange
      Off-exchange %
      34.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $875.3M
      Net income (FY)
      $70.8M
      EPS diluted
      $10.48
      View
      Buybacks
      Authorized
      $25.0M
      Remaining
      $19.8M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      10
      View
      Exempt Offerings
      Offering
      $15.0M
      Filed
      Oct 17, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 7, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jul 3, 2024; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      NUTX +15.6% +15.0% +84.2% +27.1% +13.9%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +15.2% +10.6% +70.4% +23.2% +0.0%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $25.00M
      Spent (derived)
      $5.20M
      Remaining
      $19.80M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1479681 CUSIP 67079U306 13F (30d) 144 filings 144 filers Visit website